Benzinga | Aug 9, 2021 07:05AM EDT

Dicerna Pharmaceuticals Q2 EPS $(0.53) Misses $0.41 Estimate, Sales $41.34M Miss $91.29M Estimate

Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $0.41 by 229.27 percent. This is a 23.26 percent decrease over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $41.34 million which missed the analyst consensus estimate of $91.29 million by 54.72 percent. This is a 2.20 percent increase over sales of $40.45 million the same period last year.